Printer Friendly

UNIGENE TO CONSTRUCT GMP MANUFACTURING FACILITY FOR CALCITONIN AND PROPRIETARY ENZYME

 FAIRFIELD, N.J., May 24 /PRNewswire/ -- Unigene Laboratories, Inc. (NASDAQ: UGNE), today announced plans to construct a GMP (Good Manufacturing Practice) manufacturing facility for the production of pharmaceutical-grade calcitonin.
 The 32,000-square-foot facility, which has been designed by the international engineering firm of John Brown E&C, will cost between $7-8 million and will be located in Boonton, N.J. Construction of the facility has begun and is targeted for completion around the middle of 1994. Initial capacity of the plant will be 0.5-1 kilogram of calcitonin annually, currently valued at approximately $5 million per kilogram. The plant may eventually be capable of producing up to 10 kilograms of calcitonin.
 The manufacturing plant will also produce Unigene's proprietary amidating enzyme for use in preparing calcitonin. Eventually, the quantities of amidating enzyme to be manufactured may be sufficient to produce approximately 120 kilograms of calcitonin annually. Unigene intends to establish a joint venture with one or more strategic partners to achieve this level of peptide production.
 The facility also has been designed to take advantage of the time and cost savings of Unigene's patented process for the production of other peptide hormones such as growth hormone releasing factor and calcitonin gene-related peptide. Such additional products will be able to be manufactured in the facility with the same equipment and amidating enzyme that will be used for calcitonin.
 "We are extremely excited about entering this new stage of development," stated Dr. Warren P. Levy, president of Unigene. "This strategy will allow us to generate cash flows from product sales and strategic associations, capitalize on our expertise in efficient calcitonin production and retain control of the key elements of our proprietary process. The prospects are extremely bright for significant calcitonin sales for use in animal research and human clinical investigations prior to FDA approval."
 -0- 5/24/93
 /CONTACT: Dr. Warren P. Levy, president of Unigene, 201-882-0860/
 (UGNE)


CO: Unigene Laboratories, Inc. ST: New Jersey IN: MTC SU:

TS-GK -- NY002 -- 1593 05/24/93 10:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 24, 1993
Words:335
Previous Article:MOTOROLA DESIGNATES TOP DEVELOPERS AS PLATINUM MEMBERS IN THIRD-PARTY PROGRAM; RECOGNIZES CONTRIBUTIONS TO SUCCESS OF 68000 FAMILY
Next Article:INTEGRATED HEALTH SERVICES COMPLETES $100 MILLION BANK FACILITY
Topics:


Related Articles
UNIGENE SIGNS LETTER OF INTENT FOR CALCITONIN JOINT VENTURE IN CHINA
UNIGENE SIGNS LETTER OF INTENT FOR CALCITONIN JOINT VENTURE IN CHINA
UNIGENE TO EXPAND OSTEOPOROSIS FOCUS IN COLLABORATION WITH YALE UNIVERSITY SCHOOL OF MEDICINE
UNIGENE LABORATORIES COMPLETES $2 MILLION DEBT FINANCING
UNIGENE LABORATORIES EXTENDS CLASS B WARRANT EXPIRATION DATE
UNIGENE LABORATORIES BEGINS PRODUCING OSTEOPOROSIS DRUG; GMP STATUS EXPECTED NEXT QUARTER
UNIGENE COMPLETES CALCITONIN JOINT VENTURE AGREEMENT FOR CHINA
UNIGENE'S OSTEOPOROSIS PILL EXCEEDS PERFORMANCE Target In All Subjects In Latest Phase 1 Clinical Trial
Unigene Awarded New U.S. Patent on Manufacturing Process for Osteoporosis Product

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters